RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--More than half of pharmaceutical companies — and 71% of the largest companies — maintain a dedicated counter-generics strategy team to oversee product patent expirations.
“Post-Patent Generic and Biosimilar Defense: Harnessing Competitive Tactics to Mitigate Revenue Erosion”
These dedicated teams begin planning counter-generics strategies early in a product’s lifecycle and leverage past experience to create new strategies. However, small or new pharma companies may not need a team to constantly form new counter-generics strategies, especially if the company does not often face patent expiration.
The study, “Post-Patent Generic and Biosimilar Defense: Harnessing Competitive Tactics to Mitigate Revenue Erosion,” found that the three most commonly involved departments in counter-generics planning are:
- Market research/competitive intelligence (90%)
- Product/brand management (87%)
- Business development (81%)
The three least common departments, but still present at more than 50% of companies surveyed each, are discovery (52%), quality assurance/quality control (55%) and clinical development (58%).
Surveyed Top 10 pharmaceutical companies most commonly involve product/brand management (94%) in counter-generics efforts. The least commonly involved departments at these companies are sales (56%) and discovery (56%). The low level of sales teams’ involvement shows that Top 10 companies rely on strategies focused more heavily on counter-promotion.
Cutting Edge Information also surveyed Top 50 companies and found that they most frequently involve lifecycle management, market research/competitive intelligence and sales in their counter-generics efforts. All surveyed small companies involve business development, market research/competitive intelligence and sales in their counter-generics strategies.
Small drug companies report lower levels of government/public affairs departments’ involvement, at 56%. “In contrast, 81% of Top 10 companies and 67% of Top 50 companies surveyed involve government/public affairs teams,” said David Richardson, research manager at Cutting Edge Information. “This distribution shows that company size influences an organization’s likelihood of utilizing government/public affairs in counter-generics planning.”
“Post-Patent Generic and Biosimilar Defense: Harnessing Competitive Tactics to Mitigate Revenue Erosion,” (http://www.cuttingedgeinfo.com/research/portfolio-management/counter-generics/) profiles more than 15 counter-generics strategies, team structures and staffing, and includes 39 case studies of companies’ approaches to combating generics.
Use this report to:
- Plan for and implement a diverse and robust set of strategies.
- Build a strong counter-generics task force early.
- Prepare for emerging biosimilar competition and changing approval pathways.
For more information about Counter-Generics and Biosimilars, contact Cassie Demeter at 919-403-6583.